Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Acquisitions & Divestments (2020 - 2026)

RxSight filings provide 6 years of Change in Acquisitions & Divestments readings, the most recent being $90.0 million for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 63.64% to $90.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $260.0 million, a 7.0% increase, with the full-year FY2025 number at $260.0 million, up 7.0% from a year prior.
  • Change in Acquisitions & Divestments hit $90.0 million in Q4 2025 for RxSight, up from $60.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $90.0 million in Q1 2022 to a low of $15.0 million in Q3 2021.
  • Median Change in Acquisitions & Divestments over the past 5 years was $55.0 million (2023), compared with a mean of $54.6 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: surged 400.0% in 2022 and later crashed 33.33% in 2023.
  • RxSight's Change in Acquisitions & Divestments stood at $25.0 million in 2021, then surged by 80.0% to $45.0 million in 2022, then increased by 11.11% to $50.0 million in 2023, then increased by 10.0% to $55.0 million in 2024, then soared by 63.64% to $90.0 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $90.0 million (Q4 2025), $60.0 million (Q3 2025), and $50.0 million (Q2 2025) per Business Quant data.